Clinical Observation Of Xuanbai Chengqi Decoction In The Treatment Of Mycoplasma Pneumoniae Pneumonia In Children (experienced By Lung Heat And Fu Organs)

Purpose: To observe the clinical effect of Modified Xuanbai Chengqi Decoction on Mycoplasma pneumoniae pneumonia(lung heat organ sthenia syndrome)in children.Material and method: From September 2017 to September 2018,60 children admitted to the affiliated hospital of Liaoning University of Traditional Chinese Medicine and Children’s Hospital of Dalian who met the diagnosis of mycoplasma pneumoniae pneumonia with lung heat organ sthenia syndrome type,which were divided into observation group(30cases)and control group(30 cases).Western medicine basic treatment,observation group on the basis of this combined Modified Xuanbai Chengqi Decoction,control group with ambroterol oral solution.The observation period was 10 days.Before and after treatment,the disease score,TCM syndrome score,disease syndrome total score,single symptom score,laboratory test results,recovery rate,adverse reaction rate and drug combination were compared between the two groups.Results:1.In this study,60 children were enrolled,among which 3 were detached,2 in the control group and 1 in the observation group.There was no significant difference in gender,age,height and weight between the two groups(P > 0.05).2.There was no significant difference in disease score,syndrome score,total score,single symptom score and laboratory test results between the two groups(P > 0.05).3.After treatment,the disease score and the total score of the disease syndrome in the two groups were significantly lower than before treatment(P < 0.05).The syndrome score in the control group was not significantly lower on the third day after treatment(P > 0.05).The syndrome score in the observation group was significantly lower at each time point(P < 0.05).The disease score of the observation group was significantly lower than that of the control group only on the 7th day after treatment,the syndrome score was significantly lower than that of the control group at each time point after treatment,and the total disease score was significantly lower than that of the control group on the 3rd and 7th day after treatment(P <0.05).4.After treatment,the symptoms of fever and cough in the control group were significantly improved on the 3rd day,the symptoms of abdominal fullness pain disappeared on the 7th day after treatment,the symptoms of halitosis,red lips,dry stool,sodium and yellow urine were significantly improved on the 7th day after treatment,and other symptoms and signs were significantly improved or disappeared on the 10 th day after treatment(P < 0.05).In the observation group,the symptoms of fever,cough,halitosis,dry stool,sodium and urine yellow were significantly improved on the 3rd day after treatment,the symptoms of abdominal fullness pain disappeared on the 7th day after treatment,and the remaining symptoms and conditions were significantly improved on the 7th day after treatment(P <0.05).Compared with the control group,the scores of fever,fecal dryness,urine yellowing and halitosis in the observation group decreased significantly on the third day of treatment,the single score and nasal dryness score of other main symptoms decreased significantly on the 7th day of treatment(P < 0.05),and the scores of other syndromes showed no significant difference at other time points(P > 0.05).5.In the control group,the number of normal blood routine cases increased after treatment,but the difference was not significant(P > 0.05).The number of normal CRP cases was significantly higher than that before treatment(P < 0.05).The number of normal cases in the observation group was significantly higher than that before treatment(P < 0.05),and there was no significant difference between the two groups(P > 0.05).6.After treatment,the callus of observation group was higher than that of control group,but the difference was not significant(P > 0.05).The curative effect of syndrome was significantly better than that of the observation group(P < 0.05).7.During the observation,the incidence of adverse reactions and combined medication in the control group was higher than that in the observation group,but the difference was not significant(P > 0.05).Conclusion:1.Children with MPP may have the syndrome type of lung heat organ sthenia syndrome,and the symptoms are typical.Combining Modified Xuanbai Chengqi Decoction with oraladministration can improve the overall situation and syndrome performance of MPP(lung heat organ sthenia syndrome)children in the early stage and improve the main symptoms and signs of MPP children in the middle stage.And then improve the performance of the recovery and syndrome efficacy evaluation results.2.Combining Modified Xuanbai Chengqi Decoction with oral administration can reduce the incidence of adverse reactions and drug combination during treatment of MPP(lung heat organ sthenia syndrome)children,and the drug safety is high.